Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


8th Euro Global Summit on Cancer Therapy

Valencia, Spain

Adel Galal El-Shemi

Adel Galal El-Shemi

Umm Al-Qura University, Saudi Arabia

Title: Novel preclinical study of cancer targeting oncolytic adenoviruses co-expressing ING4 and TRAIL genes for treatment of Hepatocelluar Carcinoma


Biography: Adel Galal El-Shemi


Hepato-cellular carcinoma (HCC) is one of the world’s deadliest cancers and eff orts to improve its therapy have not yet impacted its poor prognosis and high associated mortality. Limited therapeutic effi cacy, high rate of resistance and signifi cant toxicity of current HCC conventional therapy constitutes the most important challenge. In turn, development of more eff ective and highly selective alternative new therapeutic approach is a critical medical need. Interestingly, application of cancer targeting gene-virotherapy (CTGVT), in which an anti-tumor gene is inserted into an oncolytic viral vector, has shown much better anti-tumor activity than that of respective gene therapy alone or oncolytic virus (e.g. oncolytic adenovirus, OAd) therapy alone. More importantly, further modifi cation of this strategy to a novel one called the cancer-targeting dual gene viro-therapy (CTDGVT), in which an excellent triplex anticancer eff ect can be achieved by the oncolytic eff ect of AOd and the additive or synergetic interaction between two anti-tumor genes encoded by this vector. Th erefore, the present research work was designed to investigate the therapeutic potential and possible synergy of this CTDGVT strategy in treatment of HCC. As the remarkable tumoricidal eff ects of ING4 gene; a new member of tumor suppressor genes, and TRAIL gene; an apoptotic ligand induces apoptosis in tumor cells, have been recently documented, herein we investigated the therapeutic effi cacy of CTDGVT strategy composed of co-administration of OAd-ING4 plus OAd-TRAIL. To achieve these objectives, we fi rstly constructed and generated the followings 3 OAds: OAd alone (i.e., not carrying any therapeutic gene), OAd- expressing ING4 gene, and OAd- expressing TRAIL gene. Next, the tumoricidal eff ect of OAd alone, OAd-ING4, OAd-TRAIL, and OAd-ING4 plus OAd-TRAIL were tested and evaluated both in vitro and in vivo, using universal human HCC cell lines and xenograft mouse model of human HCC. Results showed that each tested strategy (OAd alone, OAd- ING4, OAd-TRAIL and OAd-ING4 plus OAd-TRAIL) had resulted in signifi cant cytotoxic and inhibitory eff ects on both human cell lines and xenograft model of HCC; however, the highest effi cient eff ect was achieved by OAd-ING4 plus OAd-TRAIL combination therapy, and this advantage of CTDGVT strategy was confi rmed by the gross, histopathological, immunohistochemical, ELISA and qRT-PCR fi ndings. Th e present new preclinical data of HCC-targeting CTDGVT strategy, which composed of OAd carrying ING4 and TRAIL tumor-suppressor genes, may provide a promising approach for liver cancer gene therapy.